TY  - CONF

T1  - Risk factors for developing osteonecrosis of the jaw (ONJ) in patients receiving denosumab or zoledronic acid for bone metastases: Results from three phase 3 trials

JO  - EUROPEAN JOURNAL OF CANCER

PY  - 2013/09/01

AU  - Brown J

AU  - Saad F

AU  - Stopeck A

AU  - Fizazi K

AU  - Henry D

AU  - Diel I

AU  - De Boer R

AU  - Wang H

AU  - Braun A

ED  - 

VL  - 49

SP  - S268

EP  - S269

Y2  - 2024/12/22

ER  -